Anti-Human CD25/IL-2R alpha Reference Antibody (Daclizumab, RUO)

Description: Daclizumab (BS10572) is a research-grade recombinant antibody targeting CD25. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: IL2-RA,IL-2Rsubunitalpha,TACantigen,IL-2-RA,p55,IL2RA,IL-2receptorsubunitalpha,Interleukin-2receptorsubunitalpha,CD25
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: BIIB019,DACHYP,CAS:152923-56-3
Background: Interleukin-2 receptor subunit alpha (CD25/IL2RA) is a ~30 kDa protein. Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.
Note: For research use only. Not suitable for clinical or therapeutic use.